Is Denali Therapeutics Inc. (DNLI) a Buy, Sell, or Hold?
Denali Therapeutics Inc.
NASDAQ:DNLI
$22.65 USD
-$3.83 (-14.46%)
- Volume
- 5.78M
- Average Volume
- 1.83M
- Market Capitalization
- $3.59B
- P/E Ratio
- -7.86
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $27.30
- Year Low
- $12.58
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.28
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ryan J. Watts |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DNLI |
| CUSIP | 24823R105 |
| CIK | 0001714899 |
| Web | https://www.denalitherapeutics.com |
| Phone | 650 866 8548 |
| Currency | USD |
| Employees | 443 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.28 |
| Quick Ratio | 9.28 |
| Cash Ratio | 3.52 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.25 |
| Price / Cash Flow | -8.57 |
| Price / Book | 4.56 |
Price Target and Rating
| Average Stock Price Forecast | $35.00 |
| High Stock Price Forecast | $41.00 |
| Low Stock Price Forecast | $26.00 |
| Forecast Upside/Downside | -35.29% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.97 |
| Trailing P/E Ratio | -7.86 |
| PEG Ratio | 1.01 |
| P/E Growth | 1.01 |
| Net Income | $-512.54M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -52.20% |
| Return on Assets | -40.13% |
Financials Score
| AltmanZ Score | 4.55 |
| Piotroski Score | 1.00 |
| Working Capital | 912.6M |
| Total Assets | 1.27B |
| Ebit | -507.92M |
| Market Cap | 4.2B |
| Total Liabilities | 339.92M |
Poll Results
About Denali Therapeutics Inc. (NASDAQ:DNLI) Stock
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclero ... sis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
2026-07-09 16:01:00
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the opening plenary address, titled “Accelerating the Discovery and Development of Medicines for Neurodegeneration,” at the Alzheimer's Association International Conference® (AAIC), taking place July 12-15 in London. Dr. Watts will discuss recent scientific advances and future opportunities including new insights in the biology of disease, the use of biomarkers for diagnosis and assessment of treatment effect, and the potential for therapeutics to cross the blood-brain barrier for enhanced delivery to the brain.
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
2026-07-08 15:05:23
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Denali to Sell Priority Review Voucher for $195M Cash Boost
2026-06-19 09:40:29
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
2026-06-18 08:00:00
SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. The U.S. Food and Drug Administration (FDA) awarded the PRV to Denali following accelerated approval of the enzyme replacement therapy AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. AVLAYAH is the first FDA-approved medicine in an emerging class of biotherapeutics designed to cross the blood-brain barrier via transferrin receptor (TfR)-mediated transport.
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-05 17:32:54
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
2026-05-27 07:54:16
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum. Company's DNL593 for FTD-GRN is differentiated by restoring both extracellular and lysosomal PGRN; phase 1/2 data readout expected by end of 2026. AVLAYAH's full approval depends on confirmatory COMPASS study results; commercial performance remains unproven post-April 2026 launch.
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
2026-05-22 13:15:26
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
2026-05-18 14:23:47
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Frequently Asked Questions
-
What is the current Denali Therapeutics Inc. (DNLI) stock price?
-
Denali Therapeutics Inc.(NASDAQ:DNLI) stock price is $22.65 in the last trading session. During the trading session, DNLI stock reached the peak price of $27.3 while $12.58 was the lowest point it dropped to. The percentage change in DNLI stock occurred in the recent session was --14.46% while the dollar amount for the price change in DNLI stock was -$-3.83.
-
DNLI's industry and sector of operation?
-
The NASDAQ listed DNLI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DNLI?
-
Katie Peng | Chief Commercial Officer
Joe Lewcock | Chief Scientific Officer
Cindy Dunkle | Chief People Officer
Chris Walsh | General Counsel
Dana Andersen | Chief Technical and Manufacturing Officer -
How many employees does DNLI have?
-
Number of DNLI employees currently stands at 443. DNLI operates from 161 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
Link for DNLI official website?
-
Official Website of DNLI is: https://www.denalitherapeutics.com
-
How do I contact DNLI?
-
DNLI could be contacted at phone #650 866 8548 and can also be accessed through its website. DNLI operates from 161 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
How many shares of DNLI are traded daily?
-
The average number of DNLI shares traded daily for last 3 months was 1.83M.
-
What is the market cap of DNLI currently?
-
The market value of DNLI currently stands at $3.59B with its latest stock price at $22.65